These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1083 related articles for article (PubMed ID: 11300484)
1. Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response. Rescigno M; Valzasina B; Bonasio R; Urbano M; Ricciardi-Castagnoli P Clin Cancer Res; 2001 Mar; 7(3 Suppl):865s-870s. PubMed ID: 11300484 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402 [TBL] [Abstract][Full Text] [Related]
3. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590 [TBL] [Abstract][Full Text] [Related]
4. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169 [TBL] [Abstract][Full Text] [Related]
5. [Enhanced translational efficacy of internal ribosomal entry site-mediated mRNA in dendritic cells contributes to efficient induction of antitumor immunity]. Tan XH; Wan YH Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):399-403. PubMed ID: 17456382 [TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Liu Y; Huang H; Chen Z; Zong L; Xiang J J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636 [TBL] [Abstract][Full Text] [Related]
8. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908 [TBL] [Abstract][Full Text] [Related]
9. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Shibagaki N; Udey MC Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050 [TBL] [Abstract][Full Text] [Related]
11. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. Russo V; Cipponi A; Raccosta L; Rainelli C; Fontana R; Maggioni D; Lunghi F; Mukenge S; Ciceri F; Bregni M; Bordignon C; Traversari C J Clin Invest; 2007 Oct; 117(10):3087-96. PubMed ID: 17885685 [TBL] [Abstract][Full Text] [Related]
12. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells. Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057 [TBL] [Abstract][Full Text] [Related]
13. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352 [TBL] [Abstract][Full Text] [Related]
14. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048 [TBL] [Abstract][Full Text] [Related]
15. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286 [TBL] [Abstract][Full Text] [Related]
16. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells. Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422 [TBL] [Abstract][Full Text] [Related]
17. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Hu J; Yuan X; Belladonna ML; Ong JM; Wachsmann-Hogiu S; Farkas DL; Black KL; Yu JS Cancer Res; 2006 Sep; 66(17):8887-96. PubMed ID: 16951206 [TBL] [Abstract][Full Text] [Related]
19. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cho HI; Kim EK; Park SY; Lee SK; Hong YK; Kim TG Cancer Lett; 2007 Dec; 258(2):189-98. PubMed ID: 17931768 [TBL] [Abstract][Full Text] [Related]
20. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]